Christine Fox Sells 7,924 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Christine Fox sold 7,924 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $250,953.08. Following the completion of the transaction, the executive vice president directly owned 84,905 shares in the company, valued at $2,688,941.35. This represents a 8.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $31.51 on Wednesday. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35. The firm has a market capitalization of $36.23 billion, a PE ratio of 26.26, a P/E/G ratio of 10.54 and a beta of 0.72. The firm has a 50-day moving average of $33.01 and a two-hundred day moving average of $26.50.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period last year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Recent quarterly results and FY‑2026 guidance remain supportive — Teva reported a Q4 EPS and revenue beat and set FY‑2026 EPS guidance of 2.570–2.770, with y/y revenue growth (~11.4%), which underpins investor confidence and helps explain upward pressure on the shares. MarketBeat TEVA coverage
• Positive Sentiment: Analyst upgrades and higher price targets — multiple firms (Scotiabank, Barclays, Truist, Goldman Sachs, others) have raised targets and ratings this quarter, boosting buy-side interest and supporting the stock’s gain.
• Neutral Sentiment: Management presentations at conferences — transcripts from the Leerink and Barclays healthcare conferences are now available; investors will scan these for pipeline updates, margin/cost commentary and capital‑allocation signals but they’ve not yet produced major new guidance. Leerink transcript Barclays transcript
• Negative Sentiment: Concentrated insider selling disclosed (filings show March 5 trades) — multiple senior executives sold shares at an average price of ~$31.67, including CEO Richard D. Francis (20,025 shares) and several EVPs; such sizable, coordinated disclosures can weigh on sentiment even if sales are routine or pre‑planned. Example SEC filing (CEO sale)
• Negative Sentiment: Media reports amplifying insider sales — outlets flagged the CEO and other executive sales, which can increase investor caution and short‑term volatility even when fundamentals remain solid. Media coverage of insider sales

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TEVA. AQR Capital Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after acquiring an additional 4,732 shares in the last quarter. Focus Partners Wealth boosted its position in Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares during the last quarter. Bank of Montreal Can boosted its position in Teva Pharmaceutical Industries by 15.9% during the second quarter. Bank of Montreal Can now owns 475,937 shares of the company’s stock valued at $7,977,000 after purchasing an additional 65,191 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Teva Pharmaceutical Industries by 4.5% in the second quarter. Bank of New York Mellon Corp now owns 1,682,837 shares of the company’s stock valued at $28,204,000 after purchasing an additional 73,141 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. grew its stake in Teva Pharmaceutical Industries by 5.3% in the second quarter. Resona Asset Management Co. Ltd. now owns 360,316 shares of the company’s stock valued at $6,039,000 after purchasing an additional 18,093 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TEVA. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Jefferies Financial Group upped their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Piper Sandler reissued an “overweight” rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.